Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Patel Chem
Quarter-by-quarter operating performance
Financials of Patel Chem
Annual income statement trend
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales + | 42 | 60 | 69 | 82 | 105 | 137 |
| Expenses + | 40 | 56 | 64 | 71 | 90 | 120 |
| Operating Profit | 2 | 4 | 5 | 12 | 15 | 17 |
| OPM % | 6% | 7% | 8% | 14% | 15% | 12% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 2 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 2 | 4 | 4 | 10 | 14 | 17 |
| Tax % | 20% | 35% | 30% | 26% | 25% | 26% |
| Net Profit + | 1 | 2 | 3 | 8 | 11 | 13 |
| EPS in Rs | 5.91 | 5.05 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Patel Chem
Capital structure and asset base
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 18 | 25 |
| Reserves | 6 | 8 | 11 | 19 | 18 | 75 |
| Borrowings + | 6 | 8 | 12 | 15 | 15 | 15 |
| Other Liabilities + | 5 | 7 | 13 | 12 | 15 | 28 |
| Total Liabilities | 18 | 23 | 37 | 47 | 65 | 142 |
| Fixed Assets + | 6 | 10 | 14 | 14 | 14 | 30 |
| CWIP | 0 | 0 | 0 | 2 | 12 | 15 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 13 | 13 | 23 | 31 | 39 | 98 |
| Total Assets | 18 | 23 | 37 | 47 | 65 | 142 |
Financials of Patel Chem
Operating, investing and financing cash movement
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -24 | 2 | 2 | 6 | 2 | 11 |
| Cash from Investing Activity + | -1,978 | -4 | -3 | -6 | -7 | -19 |
| Cash from Financing Activity + | 332 | 0 | 1 | 0 | 5 | 44 |
| Net Cash Flow | -1,670 | -1 | -0 | 0 | 0 | 36 |
| Free Cash Flow | -24 | -3 | -2 | 3 | -9 | -8 |
| CFO/OP | 13,954% | 56% | 58% | 62% | 32% | 90% |
Financials of Patel Chem
Working capital efficiency and return ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 56 | 58 | 79 | 68 | 73 | 79 |
| Inventory Days | 15 | 12 | 45 | 64 | 61 | 61 |
| Days Payable | 47 | 35 | 77 | 52 | 51 | 67 |
| Cash Conversion Cycle | 25 | 35 | 47 | 79 | 83 | 73 |
| Working Capital Days | -1 | 6 | 19 | 29 | 57 | 51 |
| ROCE % | 28% | 26% | 39% | 35% | 22% |
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…